Incyte Corp. closed 32.26% below its 52-week high of $83.95, which the company achieved on November 8th.

Incyte (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast ...

Incyte Corp. closed 34.28% below its 52-week high of $83.95, which the company achieved on November 8th.

A Federal Circuit panel looked likely to reverse a district court’s order blocking Sun Pharmaceutical Industries Ltd. from ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Even inadvertent participation by a law clerk on a matter involving their future employer may call into question the court’s ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

The US Court of Appeals for the Federal Circuit vacated a preliminary injunction on Leqselvi’s launch, lifting restrictions ...

Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

UBS lowered the firm’s price target on Incyte (INCY) to $61 from $69 and keeps a Neutral rating on the shares. The stock has held up since the ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Emkay Global Financial Services, in a client note, described the development as “materially positive,” as it removes a key ...